Discovering drugs faster

What if there was a computer that could discover medicine?

This is what Recursion has set out to do. Recursion aims to radically improve the lives of patients and those who love them by using state-of-the-art lab automation and machine learning to make new drug discoveries. The biotech company runs one of the most powerful supercomputers in the world to surface biological insights while removing human biases.

Its drug discovery engine, the Recursion OS platform, combines various technological advances such as lab robotics, computer vision, highly scaled CRISPR experimentation tools, cell culturing, and many other technologies to generate a unique, highly dimensional dataset. Recursion executes up to 2.2 million wet-lab experiments weekly and has amassed 23 petabytes of data with 3 trillion searchable relationships, which is one of the largest proprietary in-vitro biological and chemical datasets out there.

In the past year, the company initiated five clinical trials to bring potential new medicines to patients, including three Phase 2 programs aimed at “underserved” diseases that have no current treatment options. They were a rare inherited cancer predisposition syndrome, a genetic disease that causes tumors in the nervous system, and a neurovascular disease that causes enlarged blood vessels in the spinal cord and brain.

Additionally, Recursion has shown that they can save time and money in the incredibly time-intensive and costly drug-discovery process. Across all of Recursion’s programs, the company has demonstrated they can advance a medicine into the early stages of drug discovery and development about 80% faster than and at half the cost of industry averages

.